Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522651 | 0.84 | TRPV3 (0.45) | TRPV3FFAR4KCNH2ALOX5AP | |
| SCHEMBL4452048 | 0.79 | HTR7 (0.47) | TRPV3FFAR4KCNH2ALOX5AP | |
| SCHEMBL14545220 | 0.77 | CCR1 (0.44) | TRPV3KCNH2ALOX5AP | |
| SCHEMBL13020000 | 0.76 | IDH1 (0.42) | TRPV3 | |
| SCHEMBL30656311 | 0.76 | — | — | |
| SCHEMBL6792102 | 0.76 | — | — | |
| SCHEMBL7898210 | 0.75 | CYP3A4 (0.42) | TRPV3FFAR4KCNH2ALOX5AP | |
| SCHEMBL22550725 | 0.75 | TRPV3 (0.40) | TRPV3FFAR4KCNH2ALOX5AP | |
| SCHEMBL7886380 | 0.75 | TRPV3 (0.40) | TRPV3FFAR4KCNH2ALOX5AP | |
| SCHEMBL2370822 | 0.75 | NUDT1 (0.50) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-04 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-01-25 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732104-B2 | Ether compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362433-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, C9, TFPI | TRPV3 4017/4885MAPT 3995/4885FFAR4 2142/4885 |
| US-20190202808-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | TRPV3 445/4885MAPT 3425/4885FFAR4 261/4885 |
| US-20180022766-A1 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | TFPI, CFD, C9 | TRPV3 3846/4885MAPT 3823/4885FFAR4 1120/4885 |
| US-20150239920-A1 | Ether Compounds for Treatment of Complement Mediated Disorders | TFPI, CFD, C9 | TRPV3 3846/4885MAPT 3823/4885FFAR4 1120/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | TRPV3 445/4885MAPT 3425/4885FFAR4 261/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | TRPV3 445/4885MAPT 3425/4885FFAR4 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.